AbbVie in cooperation with Neurocrine Biosciences, Inc. announced positive top-line results from the first of two ongoing Phase III clinical...
AbbVie in cooperation with Neurocrine Biosciences, Inc. announced the initiation of the first of two planned Phase III clinical studies...
Ipsen announced that the FDA has approved a supplemental indication for Somatuline Depot (lanreotide) Injection 120 mg for the treatment...
The European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for a once-monthly intramuscular depot formulation of Abilify...
The goal of this clinical research study is to learn how ipilimumab in combination with Lupron (leuprolide acetate) affects the body's own defense (immune) system before having surgery to remove prostate cancer.
Ipsen has announced that Somatuline Depot (lanreotide) Injection 120 mg was approved by the FDA for the treatment of adult...
A Phase III study of once-monthly Abilify (aripiprazole intramuscular depot formulation) from Otsuka/Lundbeck for the maintenance treatment of Schizophrenia, showed that...
Mapi Pharma announced positive top-line results from the GA Depot (a long acting glatiramer acetate) Phase III clinical trial assessing the efficacy, safety and tolerability of a once monthly GA Depot 40 mg compared to placebo in relapsing forms of multiple sclerosis (RMS) patients
Viatris Inc. has been informed that Mapi Pharma Ltd. has received a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for GA Depot 40 mg from the FDA
The FDA has accepted the application from Otsuka Pharma for Abilify Depot,the once a month version of aripiprazole and Otsuka...